We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+64.75%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$415M
AUM Growth
-$87.3M
Cap. Flow
-$197M
Cap. Flow %
-47.49%
Top 10 Hldgs %
52.5%
Holding
125
New
21
Increased
12
Reduced
28
Closed
39

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$11.8M
2
PCVX icon
Vaxcyte
PCVX
+$9.81M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7M
4
RCUS icon
Arcus Biosciences
RCUS
+$3.8M
5
BTAI icon
BioXcel Therapeutics
BTAI
+$3.78M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.8M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.03M
3
GOSS icon
Gossamer Bio
GOSS
+$4.98M
4
SAGE
Sage Therapeutics
SAGE
+$3.44M
5
SCPH
scPharmaceuticals
SCPH
+$3.13M

Sector Composition

Rank Sector Weight
1 Healthcare 57.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STSA
76
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$122K 0.03%
136,059
– –
DSGN icon
77
Design Therapeutics
DSGN
$761M
$119K 0.03%
+11,568
New +$157K
FNCH
78
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$114K 0.03%
7,918
– –
SPPI
79
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$65.2K 0.02%
176,980
– –
CRBP icon
80
Corbus Pharmaceuticals
CRBP
$166M
$43.9K 0.01%
13,239
– –
TCDA
81
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
$22.3K 0.01%
145,700
-431,900
-75% -$1.28M
MDGL icon
82
Madrigal Pharmaceuticals
MDGL
$10.8B
$21.8K 0.01%
+75
New +$7.33K
GOSS icon
83
Gossamer Bio
GOSS
$82.9M
$13.2K ﹤0.01%
6,100
-604,307
-99% -$4.98M
DSGN icon
84
CALL
Design Therapeutics
DSGN
$761M
$8.21K ﹤0.01%
+800
New +$10.8K
PHXM
85
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$1.19K ﹤0.01%
302
– –
AKRO
86
CALL
DELISTED
Akero Therapeutics
AKRO
– –
-40,900
Closed -$1.39M
ALNY icon
87
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-2,800
Closed -$560K
AMLX icon
88
CALL
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-250,000
Closed -$7.04M
AXSM icon
89
PUT
Axsome Therapeutics
AXSM
$11.2B
– –
-407,600
Closed -$18.2M
BIIB icon
90
PUT
Biogen
BIIB
$30B
– –
-53,200
Closed -$14.2M
CLNN icon
91
CALL
Clene
CLNN
$64M
– –
-16,130
Closed -$903K
CLNN icon
92
PUT
Clene
CLNN
$64M
– –
-8,870
Closed -$496K
GOSS icon
93
CALL
Gossamer Bio
GOSS
$82.9M
– –
-526,600
Closed -$6.31M
GOSS icon
94
PUT
Gossamer Bio
GOSS
$82.9M
– –
-17,400
Closed -$209K
INSM icon
95
CALL
Insmed
INSM
$21.4B
– –
-100,000
Closed -$2.15M
IVA
96
Inventiva
IVA
$1.06B
– –
-13,236
Closed -$48K
MCRB icon
97
Seres Therapeutics
MCRB
$46.8M
– –
-6,566
Closed -$843K
MIST icon
98
CALL
Milestone Pharmaceuticals
MIST
$138M
– –
-180,300
Closed -$1.66M
MIST icon
99
PUT
Milestone Pharmaceuticals
MIST
$138M
– –
-338,000
Closed -$3.11M
PRAX icon
100
CALL
Praxis Precision Medicines
PRAX
$8.58B
– –
-4,947
Closed -$168K
1 2 3
4
5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Ikarian Capital held 125 positions worth $415M, down 17% from $502M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Ikarian Capital withdrew a net $197M in Q4 2022, closing 39 positions and reducing 28 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $5.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 39% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Biohaven worth $11.6M.

  • Ikarian Capital's largest Q4 2022 buy was Biohaven: 837,500 shares worth $11.6M.
  • Ikarian Capital added most to Prometheus Biosciences, Inc. Common Stock in Q4 2022, an estimated $3.74M increase.
  • Ikarian Capital's biggest Q4 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $12.8M.
  • Ikarian Capital fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $5.03M.
  • Ikarian Capital's ten largest holdings make up 53% of its $415M portfolio in Q4 2022.
  • Ikarian Capital opened 21 new positions and closed 39 in Q4 2022.
  • Ikarian Capital's portfolio value fell 17% quarter-over-quarter to $415M.

Based on Ikarian Capital's 13F filing for Q4 2022, filed 14 Feb 2023.